CLINICAL TRIALS PROFILE FOR ANAMORELIN
✉ Email this page to a colleague
Clinical Trials for Anamorelin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00622193 ↗ | Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer | Completed | Helsinn Therapeutics (U.S.), Inc | Phase 2 | The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer. |
NCT01387269 ↗ | Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1) | Completed | Helsinn Therapeutics (U.S.), Inc | Phase 3 | The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength. |
NCT01387282 ↗ | Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2) | Completed | Helsinn Therapeutics (U.S.), Inc | Phase 3 | The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength. |
NCT01395914 ↗ | Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) | Completed | Helsinn Therapeutics (U.S.), Inc | Phase 3 | The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Anamorelin
Condition Name
Clinical Trial Locations for Anamorelin
Trials by Country
Clinical Trial Progress for Anamorelin
Clinical Trial Phase
Clinical Trial Sponsors for Anamorelin
Sponsor Name